SyntheticMR’s Innovative Software Receives Regulatory Approval in Canada

Report this content

SyntheticMR announced today that their quantitative imaging software solution SyMRI has received regulatory approval in Canada and can now be sold and distributed in this market.

“We are thrilled to be able to offer our SyMRI software to the Canadian market,” says Kyle Frye, President of SyntheticMR Inc. “With this expansion, we now have access to all North American markets. This opens the door to a plethora of opportunities for SyntheticMR and I am excited to see how we enable radiologists in this region to make better, more informed decisions using quantitative imaging.”

SyMRI NEURO is designed to help you save valuable time by reducing scan time, all the while aiding as an objective decision support for diagnosis and patient follow-ups. In a single fast scan SyMRI NEURO offers a fast and standardized protocol with clinically relevant quantitative data for more robust assessments of patients. Additionally, SyMRI NEURO provides automatic segmentation of tissue such as myelin volumes, quantification of white matter, gray matter, cerebrospinal fluid and brain parenchymal volume, and data-driven diagnostic support.

SyMRI MSK provides more information in less time. One single fast scan produces quantitative T1, T2, and PD maps and a series of contrast-weighted images, for both clinical use and advanced research. SyMRI MSK also gives the radiologist more control over the image quality by making it possible to change echo time (TE), repetition time (TR), and inversion delay (TI) post-scan.

For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 or Kyle Frye, President SyntheticMR Inc. at +1 (859) 512-9496 or

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from a single 5-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative data on the brain. SyMRI MSK provides multiple contrast images and quantitative data for knee and spine anatomies. SyMRI NEURO is CE-marked and FDA 510(k) cleared and SyMRI MSK is CE-marked. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden. For more information, visit